• 

  Reuters

  Stock market drives U.S. households to record wealth

  Household net worth rose 3.7% to $154.28 trillion in the period from April through June from $148.79 trillion at the end of the first quarter, the Fed said in its quarterly snapshot of the balance sheets of households, businesses and federal, state and local governments. The data showed households have fully recouped the wealth losses generated by a crushing bear market for stocks and weaker real estate values through much of last year as the Fed kicked off an aggressive campaign to rein inflation through large, rapid-fire interest rate increases.

• 

  TipRanks

  Don’t be fooled, Ken Fisher says – this bull market has legs. Here are 2 stocks he’s using to bet on a bounce

  The best investors will often tell you that one vital ingredient for stock market success is an overlooked and underappreciated one: patience. With this year’s bull market appearing to stall, billionaire stock picker Ken Fisher reminds investors that it’s a quality needed to weather the more difficult periods, which are also a natural component of any bull market. “Volatility isn’t a flaw in this bull market. It is a feature of all bull markets, which proverbially climb a ‘Wall of Worry,’” the F

• 

  Benzinga

  EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System Cancers

  Plus Therapeutics Inc (NASDAQ: PSTV) has expanded its supply agreement with Biocept Inc (NASDAQ: BIOC) by acquiring an option to exclusively license Biocept's CNSide, a cerebrospinal fluid (CSF)-based tumor cell capture and enumeration platform, for patients receiving CNS radiotherapy. Under the terms of the agreement, CNSide developer Biocept has granted Plus Therapeutics a non-exclusive license to its CNSide cell enumeration assay for Plus' investigational therapy for leptomeningeal metastases

• 

  Exec Edge

  Plus Therapeutics Expands Biocept Partnership with Diagnostic Platform

  By Daniella Parra Plus Therapeutics, Inc. (Nasdaq: PSTV) has expanded its partnership with Biocept with an exclusive option to license a diagnostic platform for central nervous system cancer patients undergoing radiotherapy, the company said. CNSide is a proprietary assay that quantifies tumor cells in the cerebrospinal fluid of patients with various solid organ carcinomas and […]

• 

  SmartAsset

  Does It Really Pay to Buy Long-Term Care Insurance?

  If you were ever to become disabled or suffer a chronic illness or age-related debility that requires you to pay for help feeding and dressing yourself or similar assistance for an extended period, long-term care insurance could be a valuable … Continue reading → The post When to Buy Long-Term Care Insurance appeared first on SmartAsset Blog.

• 

  AP Finance

  Company pulls spicy One Chip Challenge from store shelves as Massachusetts investigates teen's death

  The maker of an extremely spicy tortilla chip sold as the One Chip Challenge and popularized as a dare on social media is pulling the product after the family of a Massachusetts teenager blamed the stunt for his death. The cause of Harris Wolobah's death last Friday hasn't been determined and an autopsy was still pending as of Thursday, but the 14-year-old's family blames the challenge. The One Chip Challenge chip sells for about $10 and comes wrapped in a sealed foil pouch that is enclosed in a coffin-shaped cardboard box.

• 

  TechCrunch

  Pinterest's new computer vision-powered body type technology to make search more inclusive

  Pinterest today announced it's introducing novel computer vision technology that will use shape, size and form to identify various body types across the more than 5 billion images on its platform, with the goal of making its search more inclusive. The company says the patent-pending technology will be used to shape its algorithms, allowing Pinterest users to see more diverse search results that include different body shapes. The feature will initially roll out to searches for women's fashion and

• 

  American City Business Journals

  Silver Spring's Aziyo Biologics is now Elutia

  Aziyo Biologics Inc., a Silver Spring biotech company that makes a range of medical devices to aid with implants, tissue repair, bone reconstruction and other procedures, is changing its name to Elutia Inc. The new name, which took effect Thursday, was chosen to reflect the company’s strategic focus on developing drug-eluting devices designed to minimize complications during surgeries. The rebranding comes ahead of the anticipated launch next year of its CanGaroo Envelope, a pouch that emits antibiotics to help lessen problems for patients receiving implantable devices such as pacemakers. The company is also developing a biologic product that aims to reduce infection during breast reconstruction surgery following a mastectomy.